Cargando…

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis

Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Frazzoni, Leonardo, Sikandar, Usama, Metelli, Flavio, Sadalla, Sinan, Mazzella, Giuseppe, Bazzoli, Franco, Fuccio, Lorenzo, Azzaroli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071154/
https://www.ncbi.nlm.nih.gov/pubmed/33920785
http://dx.doi.org/10.3390/jcm10081694
_version_ 1783683634291539968
author Frazzoni, Leonardo
Sikandar, Usama
Metelli, Flavio
Sadalla, Sinan
Mazzella, Giuseppe
Bazzoli, Franco
Fuccio, Lorenzo
Azzaroli, Francesco
author_facet Frazzoni, Leonardo
Sikandar, Usama
Metelli, Flavio
Sadalla, Sinan
Mazzella, Giuseppe
Bazzoli, Franco
Fuccio, Lorenzo
Azzaroli, Francesco
author_sort Frazzoni, Leonardo
collection PubMed
description Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV). Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively. Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26–34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17–28%) to US studies (34%, CI, 30–38%), to Egyptian studies (37%, CI, 27–47%), and to Asian studies (33%, CI, 27–40%). Sixty-eight percent (CI, 45–91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51–0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49–0.94). Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention.
format Online
Article
Text
id pubmed-8071154
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80711542021-04-26 Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis Frazzoni, Leonardo Sikandar, Usama Metelli, Flavio Sadalla, Sinan Mazzella, Giuseppe Bazzoli, Franco Fuccio, Lorenzo Azzaroli, Francesco J Clin Med Review Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV). Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively. Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26–34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17–28%) to US studies (34%, CI, 30–38%), to Egyptian studies (37%, CI, 27–47%), and to Asian studies (33%, CI, 27–40%). Sixty-eight percent (CI, 45–91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51–0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49–0.94). Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention. MDPI 2021-04-15 /pmc/articles/PMC8071154/ /pubmed/33920785 http://dx.doi.org/10.3390/jcm10081694 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Frazzoni, Leonardo
Sikandar, Usama
Metelli, Flavio
Sadalla, Sinan
Mazzella, Giuseppe
Bazzoli, Franco
Fuccio, Lorenzo
Azzaroli, Francesco
Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
title Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
title_full Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
title_fullStr Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
title_full_unstemmed Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
title_short Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
title_sort hepatocellular carcinoma recurrence after hepatitis c virus therapy with direct-acting antivirals. a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071154/
https://www.ncbi.nlm.nih.gov/pubmed/33920785
http://dx.doi.org/10.3390/jcm10081694
work_keys_str_mv AT frazzonileonardo hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT sikandarusama hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT metelliflavio hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT sadallasinan hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT mazzellagiuseppe hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT bazzolifranco hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT fucciolorenzo hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis
AT azzarolifrancesco hepatocellularcarcinomarecurrenceafterhepatitiscvirustherapywithdirectactingantiviralsasystematicreviewandmetaanalysis